HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer’s disease with AGB101: Baseline Tau and MRI imaging characteristics

levetiracetam low dose (AGB101) - AgeneBio

R. Mohs1; S. RosenzweigLipson1; A. Bakker 2; E. Chang2; N. Rani 2; R. Barton1; M. Gallagher1,2

Oct 5, 2022